The action furthers recently installed GSK CEO Emma Walmsley’s plan to purge the Big Pharma of its rare disease programs.

Belgian biotech Galapagos has chalked up a positive phase 2a trial for its idiopathic pulmonary fibrosis (IPF) drug GLPG1690, saying it halted the relentless…

A 2016 Fierce 15 winner Orchard Therapeutics has taken on Mark Rothera as its new president and chief.

The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.

Here's Wednesday's prescription for your biopharma news of note.

Ardelyx is cutting its workforce by nearly one-third as it looks to sharpen its focus on its phase 3 candidates.

The regimen lowered LDL cholesterol by 64%, a bigger drop than the combination of Zetia and Lipitor has achieved in other studies. 

Here's Tuesday's dose of your biopharma news of note.

Juno's top-level executives are being investigated about whether they failed shareholders by not telling them more about a trial's fatalities.